Imexhs Ltd · ASX:IME
Imexhs — H1 2020 Earnings Presentation
38 slides from Imexhs's earnings presentation, Aug 31, 2020
Slide 1: 1H20 Result
For personal use only Built by physicians for physicians 1H20 Result 31 August 2020 1
Slide 2: Innovative provider of cloud-based medical imaging software solutions
For personal use only Innovative provider of cloud-based medical imaging software solutions IMEXHS LTD | 1H20 FINANCIAL RESULTS (ASX:IME) 2
Slide 3: Agenda
For personal use only Agenda 1. 1H20 Result Overview – Dr German Arango, CEO 2. About IMEXHS – Dr German Arango, CEO 3. 1H20 Financial Overview – Tony Thomas, CFO 4. Strategy & Outlook – Dr German Arango, CEO 3
Slide 4: 1H20 Result Overview
For personal use only 1H20 Result Overview 4
Slide 5: 1H20 Financial Highlights
1H20 Financial Highlights For personal use only Sales Revenue of ARR of EBITDA of $4.5m $8.8m ($1.3m) Up 68% on pcp1, new Up 5% on pcp, 20% on a Improvement of $0.5m, contract wins & renewals constant currency basis $0.1m on like for like basis3 Recurring revenue of Closing cash of Underlying EBITDA
Slide 6: 1H20 Operational Achievements
1H20 Operational Achievements For personal use only STRONG MOMENTUM IN CORE GEOGRAPHIC MARKETS EXPANSION ON TRACK • Solid progress with contract • Key appointments made in renewals + extensions & new USA and Australia clients • ANVISA certification (received • Strong interest and initial August 2020
Slide 7: Investment in R&D, AI
INVESTMENT IN R&D, AI For personal use only • Redesigned Aquila with multi-tenant architecture to create the new business model, Aquila in the cloud • Optimization of our HIRUKO viewer for faster and stable performance, with a new backend • Improvement of Alula’s performance with a new streaming tec
Slide 8: Trading through COVID-19
Trading through COVID-19 For personal use only Early adoption of biosecurity protocols in-house to prevent transmission People Employees working from home Teleradiology capabilities have allowed our clients to have their Clients radiologists work safely Service levels to our clients maintained No ne
Slide 9: About IMEXHS
For personal use only About IMEXHS 9
Slide 10: Leading innovator in medical imaging
Leading innovator in medical imaging For personal use only • Next Generation multi-modality • Scalable, modular HIRUKOTM cloud-based medical imaging software platform provides solutions for all with > 270 customers globally complexity levels • Subscription model with >90% of • Teleradiology design a
Slide 11: Our competitive advantage
Our competitive advantage For personal use only ACCESSIBILITY CAPABILITY FLEXIBILITY AFFORDABILITY • Fully web & cloud-based • Single platform and archiving • Multi-modality • Lower cost base than • Teleradiology accessed from system • Scalable modular solutions for competitors any device or browser
Slide 12: HIRUKO medical imaging platform
HIRUKOTM medical imaging platform For personal use only Advanced Stella Vital Alma Braviz Post-processing AI 3D ADv 3D Basic Enterprise Aquila Alula Anteros Imaging Radiology Pathology Cardiology Core Platform HIRUKOTM Universal Portals Multi-Tenancy PACS/VNA Viewer Nuance 360 IMEXHS LTD | 1H20 FINA
Slide 13: End-to-end modular imaging solution
For personal use only End-to-end modular imaging solution Scan scheduled via our platform Uploaded to our platform Archived on our cloud-based platform Manages Billing } 1)Business Intelligence 2)Statistical Data 3. 4. 5. 1. 2. Radiologist Referring Physician Billing Physician Patient has interprets
Slide 14: Advanced streaming technology
Advanced streaming technology For personal use only Pixel Info Bandwidth Optimisation Other Info Any web Medical Image VNA Server Rendering Server enabled device IMEXHS LTD | 1H20 FINANCIAL RESULTS (ASX:IME) 14
Slide 15: Targeted investment in R&D
Targeted investment in R&D For personal use only Multi-tenant Visualisation tools AI tools architecture Driving better outcomes Cardiology, Enhanced pathology platforms teleradiology Client Outcomes Patient Outcomes • Optimise asset and resource utilisation • Faster diagnosis • Increased speed and e
Slide 16: Developing AI capabilities
Developing AI capabilities For personal use only • Access to over 700m images for AI development IMAGES • Provide interpretation services to enhance AI image library 726m • Create test bed for the development and training of 488m AI tools • Developed Stella AI which identifies normal and 231m pathol
Slide 17: 1H20 Financial Overview
For personal use only 1H20 Financial Overview 17
Slide 18: Strong growth in sales revenue
Strong growth in sales revenue For personal use only • Total sales revenue of $4.5m, up 68% (79% on a constant Sales Revenue currency basis) from new contract wins and renewals. (incl constant currency impact) 121% growth since 1H18 5 • Recurring revenue of $4.25m, up 71% (82% on a constant currency
Slide 19: Strong growth in ARR
Strong growth in ARR For personal use only JunJun 13 Jun 14Jun 15 Jun 16 Jun 17 Jun 18 Jun 19 20 10 Annualised Recurring Revenue • Annual Recurring Revenue (ARR) of 9 $8.8m, up 5% on pcp (20% on 8 constant currency basis) Millions 7 • Contract wins include Centro Medico 6 Buenos Aires (Colombia),Cli
Slide 20: Underlying EBITDA Improvement
Underlying EBITDA Improvement For personal use only $'000 1H20 1H19 Var Var % Recurring revenue contracts 4,249 2,485 1,764 71% • Total revenue of $4.6m, up 65% Other sales revenue 243 190 53 28% • Operating expenses up 41% on Other revenue 95 98 (3) (3%) pcp largely due to provision of Total revenu
Slide 21: Balance Sheet
Balance Sheet For personal use only $'000 Jun 20 Dec 19 Jun 19 Cash 6,294 7,150 220 Trade & other receivables 3,191 3,654 3,825 • Cash on hand of $6.3m Inventories 470 107 820 Current assets 9,954 10,911 4,865 • Continuing improvement in trade receivables (reduction in days sales Non-current assets
Slide 22: Summary Cash Flow
Summary Cash Flow For personal use only $'000 1H20 1H19 • Receipts from customers up 37% Receipts from customers 4,639 3,390 Payments to supplier & employees (5,465) (4,495) • Payments to suppliers & employees up Other operating activities (236) (51) 22% Net cash flow from operating activities (1,06
Slide 23: Strategy & Outlook
For personal use only Strategy & Outlook 23
Slide 24: Industry Trends: Healthcare IT sector
INDUSTRY TRENDS: Healthcare IT sector For personal use only Increasing use of Large, rapidly radiological Chronic global Shift from client growing but highly Increased proportion techniques in wider radiologist shortage server architecture to fragmented global of the value chain clinical application
Slide 25: FY20 Outlook
FY20 Outlook For personal use only USA – Increase sales presence Trading in second half in line with leveraging the new sales office company expectations established in Florida Brazil – Promotion activity to No net material impact to date from capitalise on ANVISA certification the COVID-19 pandemic
Slide 26: Appendix
For personal use only Appendix 26
Slide 27: Our board of directors
Our board of directors For personal use only Doug Flynn Carlos Palacio Dr Doug Lingard Damian Banks Dr German Arango Non-Executive Non-Executive Non-Executive Non-Executive CEO and Managing Chairman Director Director Director Director IMEXHS LTD | 1H20 FINANCIAL RESULTS (ASX:IME) 27
Slide 28: Our executive team
Our executive team For personal use only Dr German Arango Dr Jorge Marín Alejandro Alexander Sanz Tony Thomas Managing Director & Chief Medical Officer Varettoni Chief Technology Chief Financial Officer CEO Chief Sales Officer Officer IMEXHS LTD | 1H20 FINANCIAL RESULTS (ASX:IME) 28
Slide 29: Expanding global footprint
Expanding global footprint For personal use only Spain 15 countries USA >270 sites Mexico Honduras El Salvador Costa Rica Nicaragua Colombia Australia >600 radiologists Panama Ecuador 23 distributors Peru Brazil Bolivia 1/3 of team in R&D Paraguay Chile Uruguay IMEXHS currently operating Argentina A
Slide 30: Significant global opportunity
Significant global opportunity For personal use only • Global market is valued at US$2.7bn RIS/PACS • Estimated Put 3to growpoints bullet at 7.4% CAGR 2018 US$2.7bn • and text here Projected global RIS/PACS market of $5.0bn in 2027 2027 US$5.0bn • This only captures Radiology Imaging Systems • Furth
Slide 31: Built by physicians for physicians
Built by physicians for physicians For personal use only 2012 2016 2018 2020 Founded in Colombia Release zero IMEXHS lists New by two Professors of footprint WEB on ASX distribution Neuroradiology & viewer channel, cloud radiology software marketplace engineer 2015 2017 2019 Expand Implement solutio
Slide 32: Multiple distribution channels
Multiple distribution channels For personal use only • Established new distribution channel in April 2020 • Local specialist distributors have switched from with acceptance of IMEXHS on Ingram’s Micro major competitors to sell HIRUKOTM on an Cloud marketplace exclusive basis DISTRIBUTION CHANNELS DI
Slide 33: Our customers
Our customers For personal use only IMEXHS LTD | 1H20 FINANCIAL RESULTS (ASX:IME) 33
Slide 34: Case Study: Replacing a major competitor
Case Study: Replacing a major competitor For personal use only Clinica Las Americas LAS AMERICAS CLINIC • Group consists of 8 different companies • Incumbent unable to provide a high-tech • Third level complexity clinic imaging modality • More than 500 health professionals • IMEXHS appointed to prov
Slide 35: Award-Winning Software
Award-Winning Software For personal use only First place in CEEI 2014 Finalists in awards to European Union leading technology 2019 Awards for business development companies model • First Place in Digital Transformation Awards in the Fedesoft Awards: innovative solutions category recognition for IT
Slide 36: Glossary
Glossary For personal use only Artificial intelligence (AI) tools aid the Medical verticals are market segments Streaming technology transfers medical interpretation of radiological images that refer to specific diagnostic images from our VNA to our Web Viewer, which require access to large image de
Slide 37: Thank You
For personal use only Thank You WWW.IMEXHS.COM 37
Slide 38: Disclaimer
Disclaimer For personal use only The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipie